Barclays (LON:BARC) analyst Steven Valiquette maintained a Buy rating on Mckesson Corp . on Wednesday, setting a price target of $200, which is approximately 11.42% above the present share price of $179.5.
Valiquette expects Mckesson Corp. to post earnings per share (EPS) of $3.56 for the fourth quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in McKesson, with an average price target of $199.4.
The analysts price targets range from a high of $222 to a low of $178.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $60.81 billion and a net profit of $763 million. The company's market cap is $27.28 billion.
According to TipRanks.com, Barclays analyst Steven Valiquette is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 2.4% and a 53.70% success rate.
McKesson Corp (NYSE:MCK). engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical and Specialty Solutions; European Pharmaceutical Solutions; Medical-Surgical Solutions and Other. The U.S. Pharmaceutical and Specialty Solutions segment distributes pharmaceutical and other healthcare-related products and also provides pharmaceutical solutions to pharmaceutical manufacturers in the United States. The European Pharmaceutical Solutions segment provides distribution and services to wholesale, institutional and retail customers and serves patients and consumers in 13 European countries. The Medical-Surgical Solutions segment focuses on medical-surgical supplies and provides logistics and other services to healthcare providers in the United States. The Other segment comprises on McKesson Canada, McKesson Prescription Technology Solutions and in a joint venture. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.